open access
Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society
Affiliations- Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland
- 3rd Department of Internal Diseases and Cardiology, Warsaw Medical University, Warszawa, Poland
- Institute of Clinical Sciences, Maria Sklodowska-Curie Medical Academy in Warsaw, Warszawa, Poland
- 1st Department of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center in Kielce, Kielce, Poland
- Department of Internal Diseases and Cardiological Physiotherapy, Medical University in Lodz, Łódź, Poland
- Department of Civilization Diseases, Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, Warszawa, Poland
- 1st Department of Cardiology, Medical University in Lodz, Łódź, Poland
- Chair and Department of Infectious Diseases, the Medical University in Lublin, Lublin, Poland
open access
Abstract
The diagnosis of metabolic associated fatty liver disease (MAFLD) is significant for patients’ prognosis, as the disease accelerates the development of cardiovascular complications and, on the other hand, cardiometabolic conditions are risk factors for the development of fatty liver diseases. This expert opinion presents principles of MAFLD diagnosis and standards of management to reduce cardiovascular risks in patients with MAFLD.
Abstract
The diagnosis of metabolic associated fatty liver disease (MAFLD) is significant for patients’ prognosis, as the disease accelerates the development of cardiovascular complications and, on the other hand, cardiometabolic conditions are risk factors for the development of fatty liver diseases. This expert opinion presents principles of MAFLD diagnosis and standards of management to reduce cardiovascular risks in patients with MAFLD.
Keywords
atherosclerotic cardiovascular disease, cardiovascular risk, metabolic associated fatty liver disease, obesity, statin
About this articleTitle
Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society
Journal
Kardiologia Polska (Polish Heart Journal)
Issue
Article type
Expert opinion
Pages
207-214
Published online
2023-01-22
Page views
496
Article views/downloads
138
DOI
10.33963/KP.a2023.0022
Pubmed
Bibliographic record
Kardiol Pol 2023;81(2):207-214.
Keywords
atherosclerotic cardiovascular disease
cardiovascular risk
metabolic associated fatty liver disease
obesity
statin
Authors
Iwona Gorczyca-Głowacka
Marcin Wełnicki
Artur Mamcarz
Krzysztof J Filipiak
Beata Wożakowska-Kapłon
Marcin Barylski
Filip M Szymański
Jarosław D Kasprzak
Krzysztof Tomasiewcz
